Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer
- Conditions
- Gastric Cancer
- Registration Number
- NCT00004873
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating advanced stomach cancer.
PURPOSE: Randomized phase II trial to compare the effectiveness of different regimens of combination chemotherapy in treating patients who have advanced stomach cancer.
- Detailed Description
OBJECTIVES:
* Compare the efficacy and tolerability of docetaxel, cisplatin, and fluorouracil (TCF) versus docetaxel and cisplatin (TC) versus epirubicin, cisplatin, and fluorouracil (ECF) in patients with advanced gastric carcinoma.
* Compare the time to treatment failure, time to progression, and survival in this patient population treated with these regimens.
* Compare the quality of life during the treatment period and after failure in this patient population.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center, performance status (0 vs 1), and liver involvement (yes vs no). Patients are randomized to one of three treatment arms.
* Arm I: Patients receive epirubicin IV bolus and cisplatin IV over 4 hours on day 1 plus fluorouracil IV continuously on days 1-21.
* Arm II: Patients receive docetaxel IV over 1 hour and cisplatin IV over 4 hours on day 1.
* Arm III: Patients receive docetaxel and cisplatin as in arm II and fluorouracil as in arm I.
Treatment regimen is repeated every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed before randomization; at day 1 of courses 2, 4, and 6; and one month after treatment failure.
Patients with complete response or partial response are followed monthly for 3 months.
PROJECTED ACCRUAL: Approximately 111 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hopital Cantonal Universitaire de Geneva
🇨ðŸ‡Geneva, Switzerland